The purpose of this study was to determine the factors associated with parenteral nutrition-associated liver disease (PNALD) in infants who underwent surgery for necrotizing enterocolitis (NEC) and followed up the postoperative outcomes for long term parenteral nutrition (PN).
Introduction
Advances in parenteral nutrition (PN) have improved the management level for premature critically ill infants, which is often required to maintain their nutrition status and support growth. Accordingly, a common complication of parenteral nutrition administration, parenteral nutrition-associated liver disease (PNALD) might become common, which is characterized by cholestasis, steatosis, and can progress to liver failure that causes significant morbidity. [1, 2, 3] PNALD is especially common in infants diagnosed with NEC, who received prolonged courses of PN. [4, 5] PNALD may cause cirrhosis, portal hypertension, and end-stage liver disease. PNALD is reversible after discontinuing PN in the majority of patients. [6] In a cohort study of 78 children with intestine failure (IF), the mortality rate among those with cholestasis (direct bilirubin concentration ≥2 mg/dL) was close to 80% compared with 20% in those without cholestasis. [7] Although components of PN solution (either excess or lack of certain nutrients), the duration of PN, short bowel syndrome (SBS), prematurity, timing of enteral nutrition (EN), infections Editor: Manal Elshmaa. Data collection was approved by the research ethics board at Children's Hospital, Chongqing Medical University. All the parents of the patients enrolled signed consents. and endotoxin-induced liver injury have been postulated as potential causes of PNALD, [8, 9, 10] its etiology remains unclear. No unifying theory has been put forward to explain all the features of PNALD. Previous reviews have demonstrated that patients with NEC are at a greater risk for development of PNALD. [11] We conducted a cohort study to determine the incidence of PNALD over decades and further devised a meaningful risk assessment for development of PNALD in a subset of patients who underwent surgical treatment for NEC. Identification of these factors may assist with resolution of cholestasis before the development of parenteral nutrition-associated liver disease in this patient population.
Methods

Patients
A retrospective review of the hospital-based cohort for infants with NEC from July 2007 and May 2017 was performed at Children's Hospital of Chongqing Medical University with the approval of the institutional review board (No. 38 of ethical review (postgraduate); March, 2019). Entry criteria for this study were infants with a diagnosis of NEC who underwent surgical procedure during the study period. Surgical therapy was defined as either exploratory laparotomy (with or without intestinal resection) or surgical placement of peritoneal drains. Exclusion criteria were (1) evidence of abnormal liver biochemical testing before surgery; (2) acute pulmonary bacterial infection;
(3) gastrointestinal anomalies (aproctia, intestinal atresia, or Hirschsprung disease); (4) infants who died during acute NEC. (5) no liver biochemical testing after 14 days of PN exposure, or (6) incomplete follow-up data.
All infants with NEC were followed up in the hospital's outpatient clinic until at least 3 months of corrected age. If the patient developed PNALD, there was further follow up at the outpatient clinic. After institutional review board approval, records of patients who met inclusion criteria were retrospectively reviewed, including demographic information, physical examination findings, radiographic findings, ventilation status, diagnosis and procedure information, clinical management, laboratory data, blood culture results, length of stay (LOS), information of resected bowel segment, mortality, and discharge summaries. Maternal, prenatal, and intrapartum data, medication history (for both mother and child), mode of feeding (PN or EN), and newborn history before study entry were also abstracted from medical records.
The primary outcome measured was the risk factors for development of PNALD in infants. PNALD was defined as abnormal liver biochemical testing (serum direct bilirubin ≥2 mg/ dL) with at least 14 days of PN exposure at the time of liver disease diagnosis and exclusion of other causes of neonatal cholestasis to explain the abnormal biochemical tests, such as choledochal cyst, biliary atresia, congenital infections, viral hepatitis, and metabolic diseases. Full enteral feeding was defined as the provision of ≥100 kcal/kg/day from enteral nutrition (EN) and demonstrating a mean weight gain of ≥15 g/day for 7 days, or being discharged after discontinuing PN. The clinical outcomes of PNALD were defined as secondary outcomes, including enteral autonomy achievement, end-stage liver failure, etc.
Statistical analysis
Statistical comparisons were conducted using SPSS 22.0 software package (SPSS Inc, Chicago, IL). Factors available in clinical practice were selected from a large set of demographic, clinical, and laboratory variables. Continuous variables are shown as mean ± standard deviation (SD) when normally distributed and with equal variances. Categorical data are summarized as frequency counts and percentages and measured with the Chisquare or the Fisher exact statistic test. Variables with a P value .20 in the bivariate analysis or deemed clinically relevant were considered for inclusion in multivariable logistic regression models, with associations expressed as odds ratios (OR) to identify independent patient and institutional characteristics associated with PNALD development.
Results
Patient characteristics
Between July 2007 and May 2017, there were 143 preterm infants who underwent surgical intervention for NEC eligible for analysis. Fifty-six patients were excluded due to incomplete information (n = 29) and intestinal malformation (n = 27). Baseline demographic and clinical characteristics of the infants are shown in Table 1 . The age at diagnosis was 23.31 ± 20.61 days and about two-thirds of all of the patients were male, with a median gestational age and birth weight of 35.38 weeks and 2521.26 g respectively. Nine (10.3%) patients received vasopressor before NEC diagnosis. Twelve (13.8%) infants needed assisted ventilation. Most patients of the included infants (66, 75.9%) received enteral feeding before the diagnosis of NEC. The 16.1% of patients suffered PNALD.
We next performed the comparison of the baseline characteristics ( Table 2 ) and clinical status (Table 3 ) of the infants according to the PNALD development or not. Lower gestational age birth weight and weight at diagnosis were more frequent in patients who developed PNALD (P < .05 for each), whereas congenital heart disease were less frequently reported in patients progressing to PNALD. Additionally, lower platelet count, albumin level and progressive clinical deterioration were also associated with PNALD (Tables 2 and 3 ). Statistically significant Table 1 Baseline demographics and clinical characteristics for eligible Cohort (N = 87). (Tables 2 and 3 ).
Variables
Risk and predictive factors for PNALD
Independent predictors of PNALD by multivariable logistic regression analysis using forward selection in the full cohort are shown in Table 4 . Infants with progressive clinical deterioration, defined as increasing of abdominal distention, vomiting and bloody stool, were more than five times more likely to achieve PNALD than infants without clinical deterioration (OR, 5.605; 95% CI, 1.113-28.217; P = .037). Furthermore, congenital heart disease significantly decreased the risk of PNALD development (OR, 0.059; 95% CI, 0.006-0.551; P = .013). The other factors, like gestational age, birth weight, weight at diagnosis, albumin at onset, platelet count at onset, and other surgical interventions were not statistically significant after adjustment for the aforementioned independent predictors.
Clinical outcomes of PNALD
Clinical outcomes at a median follow-up of 37 (6-172) months are summarized in Table 5 . There were 10 deaths overall (15%). Of the 14 patients with PNALD, all were managed medically, 9 have achieved enteral autonomy after a period of home PN and reversed from the PNALD.
Discussion
NEC has been suggested to contribute to cholestasis caused by PN. Our study uniquely identified 2 independent predictors of PNALD in the infants following surgical therapy for NEC: congenital heart disease, and progressive clinical deterioration. Overall, 16.1% of the cohort developed PNALD, making it a common morbidity of infants undergoing surgical therapy for NEC. PNALD can be reversed in more than twothird of the infants when PN is stopped, and enteral autonomy can also be achieved in more than two thirds of the current patients. The prevalence of PNALD is unchanged with the technology development, although various incidences were reported. [12, 13] Direct comparison, however, must be made cautiously due to the different patient groups enrolled. The present incidence of PNALD of 16.1% is similar to that reported by other reports. [14, 15] In contrast, the present incidence was lower when compared to the incidence reported in another report, which was as high as 71% in preterm infants with gastrointestinal problems. [13] The reason for the discrepancy between studies is not known but may be in part related to the difference in the length of PN and the differences in definition of PNALD. It is noteworthy that in our study, most patients received PN for longer than 30 days.
It is very useful to predict which patients with NEC managed surgically will go on to develop PNALD, although it is also challenging to identify these high-risk patients. As reported in previous studies, PNALD has been attributed to various risk factors, including prematurity, low birth weight, sepsis, gastrointestinal surgery, and duration of PN. [16, 17, 18] Low gestational age and low birth weight were also reported as risk factors in previous studies. [13, 14, 19] In the univariate analysis of current data several factors seemed to be associated with the development of PNALD, which may provide clues about the etiology of PNALD, although that did not remain significant in the multivariate model.
The factors related to improved outcomes included congenital heart disease, which was in contrast to previous studies, some of which found no association between congenital anomalies and development of PNALD, [13, 14, 19] other researches suggested the mortality of congenital heart disease (CHD)and NEC together is substantially higher than that with each disease alone. [20, 21] Another investigation with a mixture of term and preterm infants is in keeping with the current findings, [22] which found lower morbidity and a trend towards decreased rate of death from NEC in CHD patients. The decreased risk of negative NEC-related outcomes in the context of cardiac disease suggests that NEC in infants with CHD may have a unique pathophysiology under the broad categorization of NEC. No consistent pattern of cardiac pathophysiology leading to NEC has been established in the literature. The finding of an association between CHD and decreased PNALD in surgical infants warrants further investigation.
In the current analysis, we found that progressive clinical deterioration of NEC, which mainly included increasing of abdominal distention, vomiting and bloody stool, was identified as main risk factor for development of cholestatic liver disease, associated with subsequent need for PN. Thus, it seemed that patients with progressive clinical manifestations of NEC were more likely to progress to PNALD. Clinical deterioration with disrupted intestinal integrity may potentiate the local inflammatory response and in turn increase the severity of NEC, and the need for prolonged PN. The surgical factors (pneumatosis intestinalis, portal venous gas, pneumoperitoneum, etc.) are associated with increased severity of NEC and consequently require prolonged duration of PN. [23] We did not find any associations of surgical factors with PNALD as our data did not support this relation in patients with NEC, although there was a trend towards association with some surgical factors in the PNALD group. This might be explained by the small number of patients, particularly in the PNALD group.
The use of the fish oil emulsion in PN is a relatively new therapy without well-defined criteria for initiation. Fish oil emulsion as source of lipids can effectively shorten the duration of cholestasis. [24, 25] Unfortunately, the fish oil has not been administered in our institute, yet. Another concern was the material of central venous lines. Bis (2-ethylhexyl) phthalate (DEHP)-plasticized polyvinyl chloride (PVC) infusion sets could affect human fertility and increase the risk of PN-associated cholestasis and must be avoided during the administration of parenteral nutrition (PN). [26] Here in our institute, this material was abandoned for many years.
The present study should be interpreted with certain limitations in mind. First, data were collected locally from a single institution, the main limitations in our study are inherent to retrospective reviews. Another limitation of this study is small sample size. Although we have performed multivariate regression analyses, controlling for confounders is less rigorous for retrospective analysis and limited samples than in randomized controlled trials, which may limit the generalizability of the results. The general PN protocols were performed in our hospital over a long period of time; therefore, there may have been many practice changes by neonatologists and pediatric surgeons, leading to different care practices between study patients, which can lead to variability in treatment and not reflect the outcomes from current treatment algorithms.
Conclusions
In summary, PNALD is a common morbidity and presents as early as 2 weeks after induction of PN among patients undergoing surgery for NEC. We noted the favorable outcomes for PNALD in the presence of CHD, which supports the notion that cardiogenic NEC (CNEC) should be considered in the NEC population. Further studies should be performed to assess the differences and characteristics of CNEC.
